A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study

Radiation Oncology

Masaya Miyazaki¹  Satoru Kakizaki²  Ken Shirabe³  Shintaro Shiba⁴  Kei Shibuya⁴  Takuya Kaminuma⁴  Takashi Nakano⁴  Hiroyuki Katoh⁵  Tatsuya Ohno⁶ 

[1] Department of Applied Medical Imaging, Gunma University Graduate School of Medicine;Department of Gastroenterology and Hepatology Science, Gunma University Graduate School of Medicine;Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine;Department of Radiation Oncology, Gunma University Graduate School of Medicine;Department of Radiation Oncology, Kanagawa Cancer Center;Gunma University Heavy Ion Medical Center;

关键词: Carbon ion radiotherapy;    Hepatocellular carcinoma;    Transarterial chemoembolization;    Propensity score matching;   

DOI  :  10.1186/s13014-019-1347-4

来源: DOAJ

【 摘 要 】

Abstract Background We compared clinical outcomes of carbon ion radiotherapy and transarterial chemoembolization in the treatment of hepatocellular carcinoma. Methods Data of 477 patients with hepatocellular carcinoma who had undergone carbon ion radiotherapy or transarterial chemoembolization between April 2007 and September 2016 were retrospectively reviewed. Treatment naïve patients with single HCC, who underwent carbon ion radiotherapy or transarterial chemoembolization as a primary treatment were included. Clinical outcomes of the treatments were compared after utilizing propensity score matching. Results Of 124 patients who received carbon ion radiotherapy and 353 patients who received transarterial chemoembolization, 31 and 23 patients met our inclusion criteria, respectively. After utilizing propensity score matching, 17 matched pairs of patients from each treatment group were analyzed. The median follow-up durations after carbon ion radiotherapy and transarterial chemoembolization were 43 and 32 months, respectively. The 3-year overall survival, local control, and progression-free survival rates in the carbon ion radiotherapy versus transarterial chemoembolization groups were 88% versus 58% (p < 0.05), 80% versus 26% (p < 0.01), and 51% versus 15% (p < 0.05), respectively. Conclusions Carbon ion radiotherapy showed more favorable clinical outcomes than did transarterial chemoembolization for patients with single hepatocellular carcinoma after matching patient characteristics utilizing propensity score matching. Further studies with larger patient numbers are required to confirm our results. Trial registration UMIN000036455: date of registration 22 March 2019, retrospectively registered.

【 授权许可】

Unknown